Core Insights - Microelectrophysiology reported a revenue of 336 million yuan for the first three quarters of 2025, representing a year-on-year growth of 15.65% [1] - The net profit attributable to shareholders was 41.92 million yuan, with a slight increase of 0.46% year-on-year, while the net profit after deducting non-recurring items turned positive at 24.07 million yuan [1] - In Q3 alone, the company achieved a revenue growth of 21.78% year-on-year, indicating a sustained improvement in performance post "U removal" [1] Financial Performance - For the first three quarters, the company’s revenue reached 336 million yuan, with a year-on-year increase of 15.65% [1] - The net profit attributable to shareholders was 41.92 million yuan, reflecting a year-on-year growth of 0.46% [1] - The net profit after deducting non-recurring items was 24.07 million yuan, marking a turnaround from losses [1] - In Q3, the company reported a net profit of 3.26 million yuan after non-recurring items, indicating a year-on-year recovery [1] Market Position and Strategy - Microelectrophysiology has established a comprehensive product layout in the cardiac electrophysiology field with over 30 products [1] - The company has actively responded to national centralized procurement policies, enhancing its market share [1] - The company’s three-dimensional electrophysiology surgeries have been performed in over 1,000 hospitals, with more than 80,000 surgeries completed, ranking first among domestic manufacturers [1] Product Development and Innovation - The company has made significant breakthroughs in high-end catheter products, increasing their market share in a field traditionally dominated by international firms [2] - The first batch of Magbot robotic navigation surgeries was successfully completed in February 2025, filling a technological gap in domestic magnetic-driven catheters [2] - The company’s self-developed pressure pulse catheter is in the NMPA registration phase, expected to be approved this year [2]